Could a daily pill slow Alzheimer's? new trial tests SAR448851

NCT ID NCT07688213

Not yet recruiting Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether an oral drug called SAR448851 can slow the progression of early Alzheimer's disease. It includes people with mild cognitive impairment or mild dementia due to Alzheimer's, who have brain amyloid plaques. Participants receive either the drug or a placebo daily for 48 weeks, with an optional longer-term follow-up. The study measures changes in blood markers of brain damage, brain scans, and thinking abilities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR448851 (oral capsule)
What this could lead to: If successful, this could point toward a daily pill that slows memory loss and brain damage in early Alzheimer's disease.
What could go wrong: This is an early-phase trial with only 160 participants. The drug may not improve symptoms or could cause side effects like brain swelling or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE DEMENTIA, ALZHEIMER'S TYPE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.